BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
| BCRX Stock | USD 7.50 0.01 0.13% |
Slightly above 59% of all BioCryst Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 -- BioCryst Pharmaceuticals, Inc. today announced that the compensation committee of BioCrysts board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 71,175 shares, and restricted stock units covering an aggregate of 50,025 shares, of BioCryst common stock. The options and RSUs were granted as of September 30, 2024, as inducements material to each employee entering into empl
Read at finance.yahoo.com
 |
BioCryst Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
59
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioCryst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioCryst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| MCRB | Seres Therapeutics | 6.52 | ||||
| AVXL | Anavex Life | 4.76 | ||||
| SAVA | Cassava Sciences | 3.92 | ||||
| IMUX | Immunic | 3.33 | ||||
| INMB | INmune Bio | 3.27 | ||||
| PDSB | PDS Biotechnology | 1.86 | ||||
| DAWN | Day One | 1.53 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| KZR | Kezar Life | 0.95 | ||||
| TGTX | TG Therapeutics | 0.57 | ||||
| APLS | Apellis Pharmaceuticals | 0.62 | ||||
| ATRA | Atara Biotherapeutics | 0.65 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
| AXSM | Axsome Therapeutics | 1.44 | ||||
| CGTX | Cognition Therapeutics | 2.44 | ||||
| VKTX | Viking Therapeutics | 2.88 | ||||
| PIRS | Pieris Pharmaceuticals | 3.45 | ||||
| BIVI | Biovie | 3.90 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.